查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
2001074

MRI造影劑市場：產品類型、給藥途徑、通路、應用、最終用途－2026-2032年全球市場預測

MRI Contrast Media Agents Market by Product Type, Administration Route, Distribution Channel, Application, End Use - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 194 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，MRI造影劑市場價值將達到 28.8 億美元，到 2026 年將成長至 31.1 億美元，到 2032 年將達到 49.9 億美元，複合年成長率為 8.15%。

主要市場統計數據
基準年 2025 28.8億美元
預計年份：2026年 31.1億美元
預測年份 2032 49.9億美元
複合年成長率 (%) 8.15%

對 MRI造影劑進行了權威概述，涵蓋了影響產品開發和臨床應用的化學多樣性、臨床效用和安全要求。

磁振造影（MRI）造影劑是現代診斷成像的關鍵，能夠提高組織對比度，並在廣泛的臨床適應症中實現可靠的成像。該領域化學成分多樣，不僅包括歷史上在許多診斷流程中佔據主導地位的钆基造影劑，還包括旨在滿足特定安全性和診斷目標的鐵基和錳基替代造影劑。除了化學性質外，製劑特性（例如離子或非離子性質）和分子結構（特別是钆錯合中線性螯合物和大環螯合物結構之間的差異）也會影響臨床性能和安全性。

安全審查、影像技術的進步以及法規環境的重組如何推動 MRI造影劑創新和應用方面的策略轉型。

由於多種因素的共同作用，包括加強安全監測、影像通訊協定進步以及監管和採購環境的重組，磁振造影（MRI）造影劑領域正經歷變革性的轉變。安全性問題，特別是與钆在體內滯留相關的問題，加速了人們對大環螯合劑的關注。與線性螯合劑相比，大環螯合劑具有更高的動力學穩定性，並且正在成為許多臨床路徑中的首選。同時，創新已從钆擴展到鐵基和錳基造影劑，旨在平衡診斷性能與差異化的安全性和藥物動力學特性。

到 2025 年，累積關稅將導致供應鏈重組和策略性製造決策，從而重塑整個 MRI造影劑生態系統，包括採購、購買和業務永續營運。

2025年累積關稅的實施，導致MRI造影劑生產商、經銷商和醫療服務提供者的供應鏈經濟和策略規劃發生重大調整。為此，各機構被迫重新審視其原料藥、螯合劑和成品的籌資策略，尤其關注原料供應商和契約製造的地理分佈。這種調整更強調供應的穩定性和韌性，促使供應商網路多元化，並轉向緊急庫存策略，以應對進口成本波動和運輸中斷。

清晰的細分市場分析揭示了產品化學特性、臨床應用、最終使用環境、分銷管道和給藥途徑如何共同決定策略重點。

詳細的細分分析闡明了產品特性、臨床應用案例和通路之間的相互作用，從而確定了策略重點和商業化策略。根據產品類型，產品組合通常分為離子型和非離子型製劑。離子型產品主要包括钆基藥物，這些藥物可進一步分為線性藥物和大環藥物，因為分子結構會顯著影響其在體內的穩定性和安全性。非離子型產品線涵蓋更廣泛的化學成分，包括钆基、鐵基和錳基藥物，其中非離子型钆類藥物還可根據其分子結構（如適用）進一步分為線性結構和大環結構。

美洲、歐洲、中東和非洲以及亞太地區的區域監管、臨床和供應方面的考量決定了招募模式和策略定位。

區域趨勢是產品策略、監管規劃和商業性實施的核心決定因素，並且在美洲、歐洲、中東和非洲以及亞太等主要市場之間存在差異。在美洲，臨床網路和採購集團通常優先考慮循證應用和大規模採購契約，這促使製造商優先考慮可靠的安全資料集和高效的物流系統，以支援國家和地區醫院系統。美國的法規環境和該地區的報銷結構影響著定價和打入市場策略，而北美學術機構經常主導臨床研究，為全球指南的製定做出貢獻。

在 MRI造影劑市場中，成熟的製藥公司和專業研發公司如何透過建立證據、整合供應鏈和夥伴關係來維持競爭優勢？

磁振造影造影劑領域的競爭格局由成熟的製藥和醫學影像公司以及敏捷的專業研發公司共同塑造，這些公司致力於開發新型化學結構和標靶製劑。成熟公司專注於最佳化產品組合、累積安全性證據，並在生產和分銷方面實現規模經濟。這些公司通常會投資於製劑改進、拓展新的適應症以及進行標靶臨床試驗，以保護和重新定位其現有產品，因為客戶維繫風險和螯合物穩定性問題日益凸顯。同時，中小型生物技術公司和專業製藥公司正在開發具有獨特安全性和成像功能特性的鐵基和錳基造影劑，並積極尋求合作和許可，以實現實際的商業化。

為產業領導者提供切實可行的策略，以確保供應、加強安全證據並加快臨床部署，同時降低關稅和監管風險。

領導企業若想在磁振造影造影劑領域維持並擴大領先地位，應採取一系列切實可行的策略，優先考慮安全性、供應鏈韌性和實證商業化。首先，企業應優先投資於具有成熟穩定性和安全性的分子設計和配方，同時積極收集必要的臨床數據，以支持差異化標籤並增強臨床醫生的信心。其次，企業應實現採購和製造地的多元化，以降低關稅波動和物流中斷的影響。這包括考慮關鍵原料的近岸外包和合格的雙重採購。

採用嚴謹的混合方法研究途徑，結合臨床醫師的訪談、監管審查和證據的三角檢驗，得出可操作的策略見解。

本分析所依據的研究結合了與該領域專家進行的初步定性研究、對監管和臨床文獻的全面回顧，以及與公開的臨床試驗註冊資訊和專利申請資訊的三角驗證。主要資訊來源包括對臨床放射科醫生、藥物安全監測專家、醫院採購經理以及研發主管的結構化檢驗，旨在收集關於臨床需求、推廣障礙和供應鏈優先事項的第一手觀點。二級資訊來源包括監管公告、同行評審的安全性和有效性研究以及與螯合化學和製劑方法相關的技術文件。

整合臨床、營運和政策要求，制定策略路徑，打造具有韌性且以患者為中心的 MRI造影劑產品組合。

總之，磁振造影造影劑市場環境正處於轉折點，安全需求、技術進步和外部政策趨勢正在塑造短期和中期策略。相關人員必須權衡钆基造影劑已確立的診斷效用與解決其在體內持久性問題的必要性，優先發展大環化學，並在臨床適用的情況下促進非钆基替代品的開發。同時，貿易政策變化帶來的營運和商業性影響，也要求重新關注供應鏈多元化和生產柔軟性，以確保患者照護的連續性。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章：MRI造影劑市場：依產品類型分類

  • 離子
  • 非離子型
    • 钆基造影劑
      • 線性造影劑
      • 大環造影劑
    • 鐵基造影劑
    • 錳基造影劑

第9章：依給藥途徑分類的MRI造影劑市場

  • 關節內給藥
  • 靜脈注射
  • 口服

第10章：MRI造影劑市場：依通路分類

  • 直銷
  • 醫院藥房
  • 網路藥房
  • 零售藥房

第11章 MRI造影劑市場：依應用領域分類

  • 腹部影像
    • 消化系統成像
    • 肝臟影像診斷
  • 心血管影像
    • 心臟影像
    • 血管影像
  • 中樞神經系統影像
  • 肌肉骨骼影像診斷

第12章 MRI造影劑市場：依最終用途分類

  • 門診手術中心
  • 診斷影像中心
  • 醫院
    • 當地醫院
    • 三級醫療醫院
  • 研究機構

第13章 MRI造影劑市場：按地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第14章 MRI造影劑市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第15章 MRI造影劑市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第16章：美國核磁共振造影劑市場

第17章：中國磁振造影造影劑市場

第18章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • Bayer AG
  • Beijing Beilu Pharmaceutical Co., Ltd.
  • Bracco Imaging SpA
  • Curium Pharma
  • Daiichi Sankyo Company, Limited
  • Fresenius Kabi AG
  • FUJIFILM Corporation
  • GE HealthCare
  • Guerbet Group
  • JB Chemicals & Pharmaceuticals Ltd.
  • Jiangsu Hengrui Medicine Co., Ltd.
  • Lantheus Medical Imaging, Inc.
  • Livealth Biopharma Pvt. Ltd.
  • Miltenyi Biotec BV & Co. KG
  • NTI Ltd.
  • Spago Nanomedical AB
  • Taejoon Pharm Co., Ltd.
  • Vitalquan, LLC
Product Code: MRR-F927BA46208C

The MRI Contrast Media Agents Market was valued at USD 2.88 billion in 2025 and is projected to grow to USD 3.11 billion in 2026, with a CAGR of 8.15%, reaching USD 4.99 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 2.88 billion
Estimated Year [2026] USD 3.11 billion
Forecast Year [2032] USD 4.99 billion
CAGR (%) 8.15%

An authoritative orientation to MRI contrast media agents that frames chemical diversity, clinical utility, and safety imperatives shaping product development and clinical adoption

Magnetic resonance imaging contrast media agents are integral to modern diagnostic imaging, enhancing tissue contrast and enabling confident interpretation across a broad range of clinical indications. The landscape is chemically diverse, encompassing gadolinium-based agents historically dominant in many diagnostic workflows, alongside iron- and manganese-based alternatives engineered to address specific safety and imaging objectives. Beyond chemistry, formulation attributes such as ionic versus non-ionic character and molecular architecture-specifically linear versus macrocyclic chelation for gadolinium complexes-inform both clinical performance and safety profiles.

Clinical utility spans abdominal, cardiovascular, central nervous system, and musculoskeletal imaging, and these applications drive nuanced requirements for relaxivity, biodistribution, and clearance. Consequently, stakeholders must weigh diagnostic benefits against evolving safety evidence and regulatory guidance. Over recent years, concerns regarding gadolinium retention in tissues and the risk, albeit low, of nephrogenic systemic fibrosis in susceptible patients have catalyzed both innovation and reappraisal of prescribing patterns. Therefore, a contemporary introduction to contrast media must foreground not only pharmacological and physicochemical attributes, but also emerging clinical best practices, risk mitigation measures, and the regulatory environment shaping product availability and labeling.

This orientation sets the stage for strategic analysis: manufacturers, clinicians, and procurement leaders benefit from a clear understanding of how molecular design, administration route, and end-use setting converge to determine clinical adoption, safety monitoring, and commercial viability. As the diagnostic imaging ecosystem evolves, this foundational perspective enables stakeholders to anticipate shifts in product preference, investment priorities, and collaborative pathways across industry and healthcare delivery systems.

How safety scrutiny, imaging technology advances, and regulatory realignment are catalyzing a strategic transformation across MRI contrast agent innovation and adoption

The landscape for MRI contrast agents is undergoing transformative shifts driven by converging forces: heightened safety scrutiny, technological advances in imaging protocols, and a reconfigured regulatory and procurement environment. Safety concerns, particularly those related to gadolinium retention, have accelerated interest in macrocyclic chelates, which offer greater kinetic stability than linear counterparts and are increasingly positioned as preferred options in many clinical pathways. Meanwhile, innovation is expanding beyond gadolinium into iron- and manganese-based agents that aim to balance diagnostic performance with differentiated safety and pharmacokinetic properties.

Concurrently, improvements in MRI hardware and sequence design are altering contrast requirements; higher-field scanners, quantitative imaging biomarkers, and AI-enhanced post-processing can increase sensitivity and may reduce the reliance on high-dose contrast administrations. These technological advances encourage manufacturers and clinical teams to re-evaluate dosing strategies and to develop agents optimized for specific imaging paradigms. Regulatory agencies are responding with more granular guidance on labeling, risk communication, and post-market surveillance, prompting manufacturers to invest in longitudinal safety studies and to strengthen pharmacovigilance infrastructures.

From a commercial perspective, these shifts are prompting strategic realignments across the value chain. Organizations are prioritizing portfolio rationalization to emphasize safer, higher-evidence products, forging cross-sector partnerships to accelerate development of non-gadolinium agents, and enhancing engagement with radiology networks to support evidence generation and adoption. As a result, the sector is transitioning from a legacy, commodity-driven model toward a differentiated, evidence-led ecosystem in which safety, clinical outcomes, and operational integration determine long-term competitive advantage.

Cumulative tariff-driven supply chain recalibrations and strategic manufacturing decisions reshaping sourcing, procurement, and operational resilience across the MRI contrast ecosystem in 2025

The introduction of cumulative tariffs in 2025 has produced a material recalibration of supply chain economics and strategic planning across manufacturers, distributors, and healthcare providers dealing with MRI contrast agents. In response, organizations have had to re-examine sourcing strategies for APIs, chelating agents, and finished formulations, with particular attention to the geographic footprint of raw material suppliers and contract manufacturers. This recalibration has increased the emphasis on supply security and resilience, prompting a shift toward diversified supplier networks and contingency inventory strategies to buffer against import cost volatility and transport disruptions.

Furthermore, the tariff environment has influenced decisions about inward investment and the localization of manufacturing capacity. Some companies are evaluating the benefits of onshore or nearshore production to reduce exposure to import duties and to shorten lead times for hospital procurement cycles. These considerations interact with regulatory timelines and quality requirements, as establishing domestic manufacturing necessitates compliance with regional regulatory frameworks and validation of manufacturing processes. From a procurement perspective, hospitals and imaging centers are renegotiating contracts and seeking pricing mechanisms that mitigate tariff-driven cost exposure, while distributors are adjusting commercial models to reflect increased landed costs and to protect margin structures.

In addition, the tariff context has amplified interest in formulations and administration strategies that reduce per-patient product consumption, including optimizing dosage protocols and supporting alternatives that offer comparable diagnostic value at lower administered mass. Finally, this period has underscored the importance of policy engagement: industry players are intensifying dialogues with trade and health authorities to clarify tariff classifications, pursue exemptions where justified for critical clinical supplies, and advocate for predictable trade policies that support uninterrupted patient care and continued innovation.

Segment-based clarity revealing how product chemistry, clinical applications, end-use settings, distribution channels, and administration routes converge to drive strategic priorities

A granular view of segmentation clarifies how product features, clinical use cases, and distribution pathways interact to define strategic priorities and commercialization tactics. Based on product type, portfolios are commonly divided into ionic and non-ionic formulations. Ionic products predominantly include gadolinium-based agents, and within that category a further distinction is drawn between linear agents and macrocyclic agents because molecular architecture significantly influences in-vivo stability and safety perceptions. Non-ionic product lines encompass a broader chemistry set that includes gadolinium-based agents, iron-based agents, and manganese-based agents, with gadolinium within the non-ionic subset also categorized by linear and macrocyclic structure when applicable.

Based on agent class, the field is organized into gadolinium-based, iron-based, and manganese-based agents, where gadolinium options are again differentiated into linear and macrocyclic forms to reflect differences in chelation stability. Based on application, contrast agents are applied across abdominal imaging, cardiovascular imaging, central nervous system imaging, and musculoskeletal imaging; abdominal imaging itself is subdivided into gastrointestinal and liver imaging while cardiovascular imaging can be decomposed into cardiac and vascular imaging to align with distinct diagnostic protocols and dosing considerations.

Based on end use, the agents are deployed in settings ranging from ambulatory surgical centers and diagnostic imaging centers to hospitals and research institutes, with hospitals further classified into community hospitals and tertiary care centers to reflect variation in case complexity and purchasing behavior. Based on distribution channel, the market engages direct sales to institutional customers as well as hospital pharmacies, online pharmacies, and retail pharmacy channels that serve outpatient demand. Finally, based on administration route, agents are employed through intraarticular, intravenous, and oral administration pathways, each of which presents different formulation, delivery device, and clinical workflow requirements that manufacturers must address in product design and commercialization planning.

Region-specific regulatory, clinical, and supply considerations across the Americas, Europe Middle East & Africa, and Asia-Pacific that determine adoption patterns and strategic positioning

Regional dynamics are a central determinant of product strategy, regulatory planning, and commercial execution, and they vary across major markets such as the Americas, Europe, Middle East & Africa, and Asia-Pacific. In the Americas, clinical networks and purchasing aggregates often emphasize evidence-led adoption and large-scale procurement agreements, which influence manufacturers to prioritize robust safety dossiers and streamlined logistics to support national and regional hospital systems. The United States regulatory environment and reimbursement structures in the region shape pricing and market entry strategies, while North American academic centers frequently lead clinical research that informs global guidelines.

Europe, Middle East & Africa presents a mosaic of regulatory frameworks and clinical practices where pan-regional harmonization efforts coexist with country-level variation. European regulatory authorities have been active on safety communication and post-market surveillance, prompting manufacturers to tailor pharmacovigilance and labeling across jurisdictions. In the Middle East and Africa, infrastructure constraints and regional procurement models create different adoption timelines, and stakeholders may prioritize cost-effective formulations and logistical simplicity when implementing contrast-enhanced imaging programs.

Asia-Pacific is characterized by rapid capacity expansion, diverse regulatory maturity, and strong manufacturing ecosystems for both API and finished products. Several markets in the region combine large patient volumes with growing diagnostic capabilities, encouraging local manufacturers and global companies to form partnerships and to invest in regional clinical evidence generation. Across these regions, strategic differentiation rests on aligning product attributes with local clinical practice, regulatory expectations, and distribution realities to optimize adoption and sustain supply continuity.

How incumbent pharmaceutical and specialty developers are pursuing evidence, supply integration, and partnerships to sustain competitive advantage in MRI contrast media

Competitive dynamics in the MRI contrast agent space are shaped by incumbent pharmaceutical and medical imaging companies, alongside nimble specialty developers advancing novel chemistries and targeted formulations. Established players focus on portfolio optimization, safety evidence generation, and scale efficiencies in manufacturing and distribution. These companies often invest in reformulations, new labeling claims, and targeted clinical studies to defend and reposition legacy products in a market increasingly attentive to retention risk and chelate stability. At the same time, smaller biotechnology firms and specialty pharmaceutical companies are advancing iron- and manganese-based agents that offer differentiated safety or functional imaging properties, driving partnerships and licensing activity as a pragmatic route to commercialization.

Strategic behaviors include vertical integration of supply chains to secure critical raw materials, collaboration with imaging device manufacturers to demonstrate product-device synergies, and selective geographic expansion guided by regulatory and clinical research priorities. In addition, there is an increasing focus on real-world evidence generation and health economics research to articulate value propositions for hospital procurement committees and payers. Distribution partners and specialty pharmacies are adapting commercial models to support complex logistics for contrast media that require cold chain management, controlled inventory oversight, and alignment with hospital formularies.

Taken together, these dynamics suggest that competitive advantage will accrue to organizations that can marry high-quality safety and efficacy evidence with reliable, flexible supply capabilities, and that can translate clinical differentiation into operational and economic benefits for healthcare providers.

Practical strategic actions for industry leaders to secure supply, strengthen safety evidence, and accelerate clinical adoption while mitigating tariff and regulatory risks

Leaders seeking to preserve and expand their position in the MRI contrast media domain should adopt a set of actionable strategies that emphasize safety, supply-chain resilience, and evidence-driven commercialization. First, prioritize investment in molecular designs and formulations with demonstrable stability and safety profiles, while advancing the clinical data necessary to support differentiated labeling and clinician confidence. Second, diversify procurement and manufacturing footprints to reduce exposure to tariff fluctuations and logistic disruptions, including evaluating nearshoring or qualified dual-sourcing for critical inputs.

Third, accelerate clinical and real-world evidence programs that directly address clinician concerns about retention and adverse events, and align these programs with regulatory reporting requirements to build trust with governing agencies. Fourth, develop commercial models that integrate with hospital formularies and imaging workflows, offering education, protocol optimization, and economic analyses to support adoption. Fifth, pursue strategic collaborations with imaging device manufacturers, academic research centers, and contract research organizations to expedite validation of agent-device synergies and to expand indications where appropriate. Finally, refine distribution strategies by blending direct sales to large institutional customers with pharmacy channel partnerships to reach outpatient markets, while ensuring rigorous cold chain and inventory controls.

By implementing these interlocking initiatives, organizations can reduce operational risk, strengthen clinical credibility, and create differentiated value propositions that resonate with radiologists, procurement leaders, and institutional payers.

A rigorous mixed-methods research approach integrating clinician interviews, regulatory review, and evidence triangulation to yield actionable strategic insight

The research underpinning this analysis combined primary qualitative engagement with domain experts, comprehensive review of regulatory and clinical literature, and triangulation against public clinical trial registries and patent filings. Primary inputs included structured interviews with practicing radiologists, pharmacovigilance specialists, hospital procurement leaders, and R&D executives to capture firsthand perspectives on clinical needs, adoption barriers, and supply chain priorities. Secondary sources encompassed regulatory communications, peer-reviewed safety and efficacy studies, and technical documentation relating to chelation chemistry and formulation approaches.

Methodologically, findings were synthesized through a layered approach: clinical insights were cross-referenced with regulatory trends to assess likely labeling and surveillance implications; manufacturing and distribution considerations were modeled qualitatively to identify resilience levers under tariff pressures; and competitive strategies were validated through analysis of corporate disclosures and partnership announcements. Emphasis was placed on extracting actionable implications rather than quantitative market sizing, and all conclusions were tested for plausibility against multiple independent sources to ensure robustness and relevance for decision-makers.

Synthesis of clinical, operational, and policy imperatives that define strategic pathways for resilient and patient-centric MRI contrast media portfolios

In conclusion, the MRI contrast media landscape is at an inflection point in which safety imperatives, technological advances, and external policy dynamics collectively shape near- and medium-term strategy. Stakeholders must balance the established diagnostic utility of gadolinium-based agents with the need to respond to retention concerns by prioritizing macrocyclic chemistries and advancing non-gadolinium alternatives where clinically appropriate. At the same time, the operational and commercial impacts of trade policy shifts necessitate a renewed focus on supply chain diversification and manufacturing flexibility to maintain uninterrupted patient care.

Looking ahead, organizations that invest in high-quality clinical evidence, engage proactively with regulators, and construct resilient distribution and production architectures will be better positioned to navigate evolving clinical preferences and procurement pressures. Collaboration across the value chain-including partnerships between specialty developers, established suppliers, imaging device firms, and healthcare providers-will accelerate the development and adoption of safer, more effective contrast solutions. Ultimately, strategic success will depend on integrating scientific rigor with operational adaptability to meet the diagnostic needs of clinicians while protecting patients and sustaining long-term commercial viability.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. MRI Contrast Media Agents Market, by Product Type

  • 8.1. Ionic
  • 8.2. Non Ionic
    • 8.2.1. Gadolinium Based Agents
      • 8.2.1.1. Linear Agents
      • 8.2.1.2. Macrocyclic Agents
    • 8.2.2. Iron Based Agents
    • 8.2.3. Manganese Based Agents

9. MRI Contrast Media Agents Market, by Administration Route

  • 9.1. Intraarticular Administration
  • 9.2. Intravenous Administration
  • 9.3. Oral Administration

10. MRI Contrast Media Agents Market, by Distribution Channel

  • 10.1. Direct Sales
  • 10.2. Hospital Pharmacies
  • 10.3. Online Pharmacies
  • 10.4. Retail Pharmacies

11. MRI Contrast Media Agents Market, by Application

  • 11.1. Abdominal Imaging
    • 11.1.1. Gastrointestinal Imaging
    • 11.1.2. Liver Imaging
  • 11.2. Cardiovascular Imaging
    • 11.2.1. Cardiac Imaging
    • 11.2.2. Vascular Imaging
  • 11.3. Central Nervous System Imaging
  • 11.4. Musculoskeletal Imaging

12. MRI Contrast Media Agents Market, by End Use

  • 12.1. Ambulatory Surgical Centers
  • 12.2. Diagnostic Imaging Centers
  • 12.3. Hospitals
    • 12.3.1. Community Hospitals
    • 12.3.2. Tertiary Care Hospitals
  • 12.4. Research Institutes

13. MRI Contrast Media Agents Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. MRI Contrast Media Agents Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. MRI Contrast Media Agents Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. United States MRI Contrast Media Agents Market

17. China MRI Contrast Media Agents Market

18. Competitive Landscape

  • 18.1. Market Concentration Analysis, 2025
    • 18.1.1. Concentration Ratio (CR)
    • 18.1.2. Herfindahl Hirschman Index (HHI)
  • 18.2. Recent Developments & Impact Analysis, 2025
  • 18.3. Product Portfolio Analysis, 2025
  • 18.4. Benchmarking Analysis, 2025
  • 18.5. Bayer AG
  • 18.6. Beijing Beilu Pharmaceutical Co., Ltd.
  • 18.7. Bracco Imaging S.p.A.
  • 18.8. Curium Pharma
  • 18.9. Daiichi Sankyo Company, Limited
  • 18.10. Fresenius Kabi AG
  • 18.11. FUJIFILM Corporation
  • 18.12. GE HealthCare
  • 18.13. Guerbet Group
  • 18.14. J.B. Chemicals & Pharmaceuticals Ltd.
  • 18.15. Jiangsu Hengrui Medicine Co., Ltd.
  • 18.16. Lantheus Medical Imaging, Inc.
  • 18.17. Livealth Biopharma Pvt. Ltd.
  • 18.18. Miltenyi Biotec B.V. & Co. KG
  • 18.19. NTI Ltd.
  • 18.20. Spago Nanomedical AB
  • 18.21. Taejoon Pharm Co., Ltd.
  • 18.22. Vitalquan, LLC

LIST OF FIGURES

  • FIGURE 1. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY ADMINISTRATION ROUTE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY END USE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. UNITED STATES MRI CONTRAST MEDIA AGENTS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 13. CHINA MRI CONTRAST MEDIA AGENTS MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY IONIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY IONIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY IONIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY NON IONIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY NON IONIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY NON IONIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY NON IONIC, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY GADOLINIUM BASED AGENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY GADOLINIUM BASED AGENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY GADOLINIUM BASED AGENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY GADOLINIUM BASED AGENTS, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY LINEAR AGENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY LINEAR AGENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY LINEAR AGENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY MACROCYCLIC AGENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY MACROCYCLIC AGENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY MACROCYCLIC AGENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY IRON BASED AGENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY IRON BASED AGENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY IRON BASED AGENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY MANGANESE BASED AGENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY MANGANESE BASED AGENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY MANGANESE BASED AGENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY INTRAARTICULAR ADMINISTRATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY INTRAARTICULAR ADMINISTRATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY INTRAARTICULAR ADMINISTRATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY INTRAVENOUS ADMINISTRATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY INTRAVENOUS ADMINISTRATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY INTRAVENOUS ADMINISTRATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY ORAL ADMINISTRATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY ORAL ADMINISTRATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY ORAL ADMINISTRATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY DIRECT SALES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY DIRECT SALES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY DIRECT SALES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY HOSPITAL PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY HOSPITAL PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY ONLINE PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY ONLINE PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY RETAIL PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY ABDOMINAL IMAGING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY ABDOMINAL IMAGING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY ABDOMINAL IMAGING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY ABDOMINAL IMAGING, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY GASTROINTESTINAL IMAGING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY GASTROINTESTINAL IMAGING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY GASTROINTESTINAL IMAGING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY LIVER IMAGING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY LIVER IMAGING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY LIVER IMAGING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY CARDIOVASCULAR IMAGING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY CARDIOVASCULAR IMAGING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY CARDIOVASCULAR IMAGING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY CARDIOVASCULAR IMAGING, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY CARDIAC IMAGING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY CARDIAC IMAGING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY CARDIAC IMAGING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY VASCULAR IMAGING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY VASCULAR IMAGING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY VASCULAR IMAGING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY CENTRAL NERVOUS SYSTEM IMAGING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY CENTRAL NERVOUS SYSTEM IMAGING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY CENTRAL NERVOUS SYSTEM IMAGING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY MUSCULOSKELETAL IMAGING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY MUSCULOSKELETAL IMAGING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY MUSCULOSKELETAL IMAGING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY END USE, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY DIAGNOSTIC IMAGING CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY DIAGNOSTIC IMAGING CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY DIAGNOSTIC IMAGING CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY COMMUNITY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY COMMUNITY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY COMMUNITY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY TERTIARY CARE HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY TERTIARY CARE HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY TERTIARY CARE HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY RESEARCH INSTITUTES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY RESEARCH INSTITUTES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 97. AMERICAS MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 98. AMERICAS MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 99. AMERICAS MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY NON IONIC, 2018-2032 (USD MILLION)
  • TABLE 100. AMERICAS MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY GADOLINIUM BASED AGENTS, 2018-2032 (USD MILLION)
  • TABLE 101. AMERICAS MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 102. AMERICAS MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 103. AMERICAS MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 104. AMERICAS MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY ABDOMINAL IMAGING, 2018-2032 (USD MILLION)
  • TABLE 105. AMERICAS MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY CARDIOVASCULAR IMAGING, 2018-2032 (USD MILLION)
  • TABLE 106. AMERICAS MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY END USE, 2018-2032 (USD MILLION)
  • TABLE 107. AMERICAS MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 108. NORTH AMERICA MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 109. NORTH AMERICA MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 110. NORTH AMERICA MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY NON IONIC, 2018-2032 (USD MILLION)
  • TABLE 111. NORTH AMERICA MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY GADOLINIUM BASED AGENTS, 2018-2032 (USD MILLION)
  • TABLE 112. NORTH AMERICA MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 113. NORTH AMERICA MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 114. NORTH AMERICA MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 115. NORTH AMERICA MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY ABDOMINAL IMAGING, 2018-2032 (USD MILLION)
  • TABLE 116. NORTH AMERICA MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY CARDIOVASCULAR IMAGING, 2018-2032 (USD MILLION)
  • TABLE 117. NORTH AMERICA MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY END USE, 2018-2032 (USD MILLION)
  • TABLE 118. NORTH AMERICA MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 119. LATIN AMERICA MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 120. LATIN AMERICA MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 121. LATIN AMERICA MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY NON IONIC, 2018-2032 (USD MILLION)
  • TABLE 122. LATIN AMERICA MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY GADOLINIUM BASED AGENTS, 2018-2032 (USD MILLION)
  • TABLE 123. LATIN AMERICA MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 124. LATIN AMERICA MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 125. LATIN AMERICA MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 126. LATIN AMERICA MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY ABDOMINAL IMAGING, 2018-2032 (USD MILLION)
  • TABLE 127. LATIN AMERICA MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY CARDIOVASCULAR IMAGING, 2018-2032 (USD MILLION)
  • TABLE 128. LATIN AMERICA MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY END USE, 2018-2032 (USD MILLION)
  • TABLE 129. LATIN AMERICA MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 130. EUROPE, MIDDLE EAST & AFRICA MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 131. EUROPE, MIDDLE EAST & AFRICA MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 132. EUROPE, MIDDLE EAST & AFRICA MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY NON IONIC, 2018-2032 (USD MILLION)
  • TABLE 133. EUROPE, MIDDLE EAST & AFRICA MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY GADOLINIUM BASED AGENTS, 2018-2032 (USD MILLION)
  • TABLE 134. EUROPE, MIDDLE EAST & AFRICA MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 135. EUROPE, MIDDLE EAST & AFRICA MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 136. EUROPE, MIDDLE EAST & AFRICA MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 137. EUROPE, MIDDLE EAST & AFRICA MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY ABDOMINAL IMAGING, 2018-2032 (USD MILLION)
  • TABLE 138. EUROPE, MIDDLE EAST & AFRICA MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY CARDIOVASCULAR IMAGING, 2018-2032 (USD MILLION)
  • TABLE 139. EUROPE, MIDDLE EAST & AFRICA MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY END USE, 2018-2032 (USD MILLION)
  • TABLE 140. EUROPE, MIDDLE EAST & AFRICA MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 141. EUROPE MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 142. EUROPE MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 143. EUROPE MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY NON IONIC, 2018-2032 (USD MILLION)
  • TABLE 144. EUROPE MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY GADOLINIUM BASED AGENTS, 2018-2032 (USD MILLION)
  • TABLE 145. EUROPE MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 146. EUROPE MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 147. EUROPE MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 148. EUROPE MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY ABDOMINAL IMAGING, 2018-2032 (USD MILLION)
  • TABLE 149. EUROPE MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY CARDIOVASCULAR IMAGING, 2018-2032 (USD MILLION)
  • TABLE 150. EUROPE MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY END USE, 2018-2032 (USD MILLION)
  • TABLE 151. EUROPE MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 152. MIDDLE EAST MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 153. MIDDLE EAST MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 154. MIDDLE EAST MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY NON IONIC, 2018-2032 (USD MILLION)
  • TABLE 155. MIDDLE EAST MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY GADOLINIUM BASED AGENTS, 2018-2032 (USD MILLION)
  • TABLE 156. MIDDLE EAST MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 157. MIDDLE EAST MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 158. MIDDLE EAST MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 159. MIDDLE EAST MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY ABDOMINAL IMAGING, 2018-2032 (USD MILLION)
  • TABLE 160. MIDDLE EAST MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY CARDIOVASCULAR IMAGING, 2018-2032 (USD MILLION)
  • TABLE 161. MIDDLE EAST MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY END USE, 2018-2032 (USD MILLION)
  • TABLE 162. MIDDLE EAST MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 163. AFRICA MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 164. AFRICA MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 165. AFRICA MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY NON IONIC, 2018-2032 (USD MILLION)
  • TABLE 166. AFRICA MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY GADOLINIUM BASED AGENTS, 2018-2032 (USD MILLION)
  • TABLE 167. AFRICA MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 168. AFRICA MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 169. AFRICA MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 170. AFRICA MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY ABDOMINAL IMAGING, 2018-2032 (USD MILLION)
  • TABLE 171. AFRICA MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY CARDIOVASCULAR IMAGING, 2018-2032 (USD MILLION)
  • TABLE 172. AFRICA MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY END USE, 2018-2032 (USD MILLION)
  • TABLE 173. AFRICA MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 174. ASIA-PACIFIC MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 175. ASIA-PACIFIC MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 176. ASIA-PACIFIC MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY NON IONIC, 2018-2032 (USD MILLION)
  • TABLE 177. ASIA-PACIFIC MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY GADOLINIUM BASED AGENTS, 2018-2032 (USD MILLION)
  • TABLE 178. ASIA-PACIFIC MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 179. ASIA-PACIFIC MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 180. ASIA-PACIFIC MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 181. ASIA-PACIFIC MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY ABDOMINAL IMAGING, 2018-2032 (USD MILLION)
  • TABLE 182. ASIA-PACIFIC MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY CARDIOVASCULAR IMAGING, 2018-2032 (USD MILLION)
  • TABLE 183. ASIA-PACIFIC MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY END USE, 2018-2032 (USD MILLION)
  • TABLE 184. ASIA-PACIFIC MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 185. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 186. ASEAN MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 187. ASEAN MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 188. ASEAN MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY NON IONIC, 2018-2032 (USD MILLION)
  • TABLE 189. ASEAN MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY GADOLINIUM BASED AGENTS, 2018-2032 (USD MILLION)
  • TABLE 190. ASEAN MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 191. ASEAN MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 192. ASEAN MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 193. ASEAN MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY ABDOMINAL IMAGING, 2018-2032 (USD MILLION)
  • TABLE 194. ASEAN MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY CARDIOVASCULAR IMAGING, 2018-2032 (USD MILLION)
  • TABLE 195. ASEAN MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY END USE, 2018-2032 (USD MILLION)
  • TABLE 196. ASEAN MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 197. GCC MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 198. GCC MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 199. GCC MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY NON IONIC, 2018-2032 (USD MILLION)
  • TABLE 200. GCC MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY GADOLINIUM BASED AGENTS, 2018-2032 (USD MILLION)
  • TABLE 201. GCC MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 202. GCC MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 203. GCC MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 204. GCC MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY ABDOMINAL IMAGING, 2018-2032 (USD MILLION)
  • TABLE 205. GCC MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY CARDIOVASCULAR IMAGING, 2018-2032 (USD MILLION)
  • TABLE 206. GCC MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY END USE, 2018-2032 (USD MILLION)
  • TABLE 207. GCC MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 208. EUROPEAN UNION MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 209. EUROPEAN UNION MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 210. EUROPEAN UNION MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY NON IONIC, 2018-2032 (USD MILLION)
  • TABLE 211. EUROPEAN UNION MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY GADOLINIUM BASED AGENTS, 2018-2032 (USD MILLION)
  • TABLE 212. EUROPEAN UNION MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 213. EUROPEAN UNION MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 214. EUROPEAN UNION MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 215. EUROPEAN UNION MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY ABDOMINAL IMAGING, 2018-2032 (USD MILLION)
  • TABLE 216. EUROPEAN UNION MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY CARDIOVASCULAR IMAGING, 2018-2032 (USD MILLION)
  • TABLE 217. EUROPEAN UNION MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY END USE, 2018-2032 (USD MILLION)
  • TABLE 218. EUROPEAN UNION MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 219. BRICS MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 220. BRICS MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 221. BRICS MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY NON IONIC, 2018-2032 (USD MILLION)
  • TABLE 222. BRICS MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY GADOLINIUM BASED AGENTS, 2018-2032 (USD MILLION)
  • TABLE 223. BRICS MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 224. BRICS MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 225. BRICS MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 226. BRICS MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY ABDOMINAL IMAGING, 2018-2032 (USD MILLION)
  • TABLE 227. BRICS MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY CARDIOVASCULAR IMAGING, 2018-2032 (USD MILLION)
  • TABLE 228. BRICS MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY END USE, 2018-2032 (USD MILLION)
  • TABLE 229. BRICS MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 230. G7 MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 231. G7 MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 232. G7 MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY NON IONIC, 2018-2032 (USD MILLION)
  • TABLE 233. G7 MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY GADOLINIUM BASED AGENTS, 2018-2032 (USD MILLION)
  • TABLE 234. G7 MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 235. G7 MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 236. G7 MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 237. G7 MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY ABDOMINAL IMAGING, 2018-2032 (USD MILLION)
  • TABLE 238. G7 MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY CARDIOVASCULAR IMAGING, 2018-2032 (USD MILLION)
  • TABLE 239. G7 MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY END USE, 2018-2032 (USD MILLION)
  • TABLE 240. G7 MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 241. NATO MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 242. NATO MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 243. NATO MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY NON IONIC, 2018-2032 (USD MILLION)
  • TABLE 244. NATO MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY GADOLINIUM BASED AGENTS, 2018-2032 (USD MILLION)
  • TABLE 245. NATO MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 246. NATO MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 247. NATO MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 248. NATO MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY ABDOMINAL IMAGING, 2018-2032 (USD MILLION)
  • TABLE 249. NATO MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY CARDIOVASCULAR IMAGING, 2018-2032 (USD MILLION)
  • TABLE 250. NATO MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY END USE, 2018-2032 (USD MILLION)
  • TABLE 251. NATO MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 252. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 253. UNITED STATES MRI CONTRAST MEDIA AGENTS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 254. UNITED STATES MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 255. UNITED STATES MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY NON IONIC, 2018-2032 (USD MILLION)
  • TABLE 256. UNITED STATES MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY GADOLINIUM BASED AGENTS, 2018-2032 (USD MILLION)
  • TABLE 257. UNITED STATES MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 258. UNITED STATES MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 259. UNITED STATES MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 260. UNITED STATES MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY ABDOMINAL IMAGING, 2018-2032 (USD MILLION)
  • TABLE 261. UNITED STATES MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY CARDIOVASCULAR IMAGING, 2018-2032 (USD MILLION)
  • TABLE 262. UNITED STATES MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY END USE, 2018-2032 (USD MILLION)
  • TABLE 263. UNITED STATES MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 264. CHINA MRI CONTRAST MEDIA AGENTS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 265. CHINA MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 266. CHINA MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY NON IONIC, 2018-2032 (USD MILLION)
  • TABLE 267. CHINA MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY GADOLINIUM BASED AGENTS, 2018-2032 (USD MILLION)
  • TABLE 268. CHINA MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 269. CHINA MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 270. CHINA MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 271. CHINA MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY ABDOMINAL IMAGING, 2018-2032 (USD MILLION)
  • TABLE 272. CHINA MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY CARDIOVASCULAR IMAGING, 2018-2032 (USD MILLION)
  • TABLE 273. CHINA MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY END USE, 2018-2032 (USD MILLION)
  • TABLE 274. CHINA MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)